Clover Health Investments (NASDAQ:CLOV) Stock Crosses Below 50-Day Moving Average – What’s Next?

Shares of Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.63 and traded as low as $4.11. Clover Health Investments shares last traded at $4.17, with a volume of 8,054,217 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CLOV. Needham & Company LLC reaffirmed a “buy” rating on shares of Clover Health Investments in a report on Thursday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Clover Health Investments in a research report on Monday, September 21st. UBS Group raised their price objective on shares of Clover Health Investments from $5.00 to $5.50 and gave the company a “neutral” rating in a research report on Thursday, November 5th. Wall Street Zen lowered Clover Health Investments from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Finally, Deutsche Bank initiated coverage on Clover Health Investments in a research report on Thursday, September 10th. They set a “buy” rating and a $6.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.10.

Check Out Our Latest Analysis on CLOV

Clover Health Investments Stock Performance

The stock’s fifty day moving average price is $4.63 and its 200-day moving average price is $3.68. The firm has a market cap of $2.23 billion, a PE ratio of 417.42 and a beta of 2.52.

Clover Health Investments (NASDAQ:CLOV – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm had revenue of $759.30 million during the quarter, compared to analysts’ expectations of $740.07 million. Clover Health Investments had a net margin of 0.45% and a return on equity of 4.66%. Sell-side analysts forecast that Clover Health Investments, Corp. will post 0.06 earnings per share for the current fiscal year.

Insider Activity at Clover Health Investments

In other news, CEO Andrew Toy sold 318,806 shares of Clover Health Investments stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.19, for a total transaction of $1,335,797.14. Following the completion of the sale, the chief executive officer directly owned 9,140,510 shares in the company, valued at approximately $38,298,736.90. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Conrad Wai sold 300,000 shares of Clover Health Investments stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $4.72, for a total transaction of $1,416,000.00. Following the sale, the chief executive officer owned 1,170,056 shares of the company’s stock, valued at approximately $5,522,664.32. The trade was a 20.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 768,573 shares of company stock valued at $3,462,479. 23.51% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Clover Health Investments

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC purchased a new stake in Clover Health Investments during the second quarter worth $2,156,000. Bank of New York Mellon Corp acquired a new stake in Clover Health Investments in the second quarter valued at $6,346,000. WINTON GROUP Ltd purchased a new position in shares of Clover Health Investments in the second quarter valued at $913,000. Lazard Asset Management LLC purchased a new position in shares of Clover Health Investments in the first quarter valued at $309,000. Finally, AXQ Capital LP increased its position in shares of Clover Health Investments by 602.6% in the second quarter. AXQ Capital LP now owns 146,569 shares of the company’s stock valued at $768,000 after buying an additional 125,708 shares in the last quarter. 19.77% of the stock is owned by institutional investors and hedge funds.

About Clover Health Investments

(Get Free Report)

Clover Health Investments is a U.S. healthcare company focused on Medicare. Its insurance business offers Medicare Advantage plans to eligible beneficiaries in select markets, combining medical coverage with support intended to help members access care. The company also developed the Clover Assistant, a technology platform that organizes patient information and provides clinicians with insights to support care decisions. Clover has described the platform as a way to help primary care providers identify health needs and coordinate care for people with complex conditions.

Further Reading

Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.